Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Avalo Therapeutics Inc (AVTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: AVTX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $33.71
1 Year Target Price $33.71
| 6 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.72% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 349.08M USD | Price to earnings Ratio - | 1Y Target Price 33.71 |
Price to earnings Ratio - | 1Y Target Price 33.71 | ||
Volume (30-day avg) 8 | Beta 0.86 | 52 Weeks Range 3.39 - 20.72 | Updated Date 12/18/2025 |
52 Weeks Range 3.39 - 20.72 | Updated Date 12/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -34632.29% |
Management Effectiveness
Return on Assets (TTM) -37.18% | Return on Equity (TTM) -174.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 238832912 | Price to Sales(TTM) 1818.12 |
Enterprise Value 238832912 | Price to Sales(TTM) 1818.12 | ||
Enterprise Value to Revenue 1243.92 | Enterprise Value to EBITDA -0.19 | Shares Outstanding 18133968 | Shares Floating 10412706 |
Shares Outstanding 18133968 | Shares Floating 10412706 | ||
Percent Insiders 3.8 | Percent Institutions 85.32 |
About Avalo Therapeutics Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2015-11-13 | President, CEO & Director Dr. Garry A. Neil M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://www.avalotx.com |
Full time employees 23 | Website https://www.avalotx.com | ||
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.